When I wrote about emerging trends in med tech early last year, I certainly did not predict the pandemic or the shutdown. While COVID-19 has had an obviously enormous impact on the American economy and on investing in general, that impact has been less severe in the life sciences sector. COVID-19 has not dampened angel investing in life sciences, nor has it derailed the explosion of emerging growth companies in this sector; in fact, it is commonly believed that the life sciences sector in 2021 will significantly outperform its 2020 results.